For the Quarter Ending September 2025
North America
• In United States, the Orlistat Price Index remained stable quarter-over-quarter in Q3 2025, balancing demand and cost factors.
• Orlistat production costs faced upward pressure from a 2.6% PPI increase in August 2025 for manufacturing inputs.
• Hexane feedstock costs moved lower in Q3 2025, driven by consistent refining operations and softened downstream intake.
• Demand for weight-loss drugs, including GLP-1 analogues, showed significant growth in 2025, supporting Orlistat market.
• Robust US retail sales, up 5.42% in September 2025, bolstered consumer spending despite weakened consumer confidence.
• A low 4.3% unemployment rate in September 2025 supported disposable income and access to health insurance.
• The global chemicals industry experienced tight margins and overcapacity in Q3 2025, affecting overall market dynamics.
• US chemical production contracted in Q3 2025, reflecting broader industrial sluggishness with minimal industrial production growth.
• Orlistat Price Forecast suggests continued stability, balancing cost pressures with sustained demand for weight management solutions.
Why did the price of Orlistat change in September 2025 in North America?
• Producer prices increased 2.6% in August 2025, raising Orlistat manufacturing input costs.
• Robust US retail sales, up 5.42% in September 2025, supported demand for health products.
• Hexane feedstock costs declined in Q3 2025, partially offsetting other production cost increases.
APAC
• In China, the Orlistat Price Index fell quarter-over-quarter, influenced by deflationary pressures and global oversupply in Q3 2025.
• Orlistat production costs were influenced by falling factory-gate prices (PPI -2.3% YoY) and steady petrochemical feedstock costs.
• Domestic pharmaceutical demand strengthened in Q3 2025, driven by an aging population and increasing chronic diseases.
• Overall domestic consumption showed weakness in Q3 2025, despite 3.0% year-on-year retail sales growth.
• China's industrial production increased 6.5% year-on-year in September 2025, supporting stable supply chains.
• The Manufacturing Index was contracting in September 2025, indicating a slowdown in broader industrial activity.
• Consumer confidence stood at 89.6 in September 2025, reflecting pessimism and reduced discretionary spending.
• Global oversupply in the chemicals market persisted in Q3 2025, with China adding significant chemical capacity.
• The pharmaceutical intermediate sector in China expanded steadily in Q3 2025, driven by cost-effective manufacturing.
Why did the price of Orlistat change in September 2025 in APAC?
• Deflationary pressures (CPI -0.3% YoY September 2025) dampened consumer purchasing power.
• A contracting Manufacturing Index in September 2025 signaled economic weakness and impacted supply chains.
• Global oversupply in the chemicals market, coupled with China's capacity additions, exerted downward pressure.
Europe
• In Germany, the Orlistat Price Index fell quarter-over-quarter in Q3 2025, influenced by a 1.7% decline in producer prices.
• Orlistat production costs in Q3 2025 saw mixed trends from eased natural gas, but elevated electricity and carbon costs.
• Orlistat demand outlook in Q3 2025 was tempered by significantly negative consumer confidence (-23.6 index).
• A contracting Manufacturing Index and 1.0% industrial production decline in September 2025 impacted Orlistat supply.
• Low unemployment (3.9%) in September 2025 supported Orlistat demand by bolstering consumer purchasing power.
• Germany's pharmaceutical market expanded in Q3 2025, providing a stable demand base for Orlistat.
• Rising CPI (2.4%) in September 2025 signaled higher operational costs for Orlistat producers.
• Modest retail sales growth (0.8%) in September 2025 indicated cautious spending on discretionary Orlistat.
Why did the price of Orlistat change in September 2025 in Europe?
• Producer prices (PPI) declined by 1.7% in September 2025, reducing Orlistat input costs.
• Consumer confidence was significantly negative (-23.6 index) in September 2025, dampening Orlistat demand.
• Elevated electricity prices for businesses in Q3 2025 increased Orlistat manufacturing operational costs.
For the Quarter Ending December 2022
North America
In North America, the CFR Los Angeles price of Orlistat API rose from $393500/mt to $396800/mt in October and November before dropping to $388500/mt in December of 2022. The first week of October saw a delay in Orlistat imports due to a one-week holiday in China, a significant exporter; nonetheless, ample supplies held by domestic retailers and strong demand maintained the market's buoyancy.
Because of the unanticipated increase in Covid cases in China that had a negative effect on the US Orlistat market, the market for Orlistat experienced a pattern change in the second half of the quarter. The broken supply chain did, however, gradually heal as the economy expanded, and there was a major decrease in port backlog in December.
Asia Pacific
During the fourth quarter of 2022, the price of Orlistat across the Asia Pacific region showed a stagnant market trend. FOB Shanghai values in China first increased from $380000/mt to 382550/mt in October and November before falling to $374200/mt in December. The closure of production facilities for the Golden Week resulted in a gradual fall in Orlistat orders for China's API market during the first week of October. After a one-week celebration and market reopening, domestic traders had to deal with various discordant signals, making it difficult for the players to catch up to the slow growth observed in some downstream sectors, but strong demand kept the market afloat. Due to plentiful supplies, Chinese producers and suppliers could satisfy demand throughout the entire quarter. In reaction to criticism and severe discontent in the country, government authorities changed its zero-covid regulations, making the country susceptible once more during the H2 of Q4 2022.
Europe
In Europe, given the settlement of CFR Hamburg prices at $391520/mt and $383280/mt in November and December, the German market for Orlistat followed the same trend as that of North America and Asia. Because of the unanticipated rise in COVID cases, which resulted in a continuous fall in demand, international demand was higher in the first part of the quarter than it was in December. Orlistat offtakes remained strong in the end-user industries despite high energy and raw material prices.
For the Quarter Ending September 2022
North America
The prices of Orlistat inclined significantly with a positive trend during the first half of Q3 in the North American region, which was supported by higher downstream demand and inquiries from the domestic market. Further, the prices started to decline following the mid-Q3 and stabilized towards the termination of the third quarter on an upper side backed by consistent requirements. Also, the local vendor had enough inventories to meet the overall demand. Eliminating the lockdown and resumption of production activities in the exporting countries kept the trading momentum firm in the international market. Overall, in the third quarter, Orlistat prices decreased with the settlement of USD 391000/MT CFR Los Angeles in the United States.
APAC
In the APAC region, the prices of Orlistat inclined significantly during the third quarter of 2022. During the H1 of Q3, the prices rose considerably at a stable rate owing to consistent demand from end-user pharmaceutical sectors and weakened inventories with the domestic market participants. Furthermore, following the H2 of Q3, the halt in production activities and port congestion led to accumulated shipments which supported the pricing tendency in the market. Moreover, towards the termination of Q3, the prices declined considerably, keeping enough inventories with the local vendor to meet the overall demand. With this, the prices of Orlistat were assessed at USD 377000/MT FOB Shanghai in China.
Europe
The prices of Orlistat witnessed a downward price trajectory in the European region during the third quarter of 2022. At the onset of Q3, the costs increased slightly compared to the previous month, in which the market participant had stockpiled inventories and could meet the demand side. There were balanced supply-demand market sentiments observed during the H1 of Q3. Further, towards the H2 of Q3, the prices started to decline significantly, keeping the market sentiments on the lower side. Additionally, the already challenging economic climate in Europe and the lockdown and port restrictions in China made the availability of downstream Orlistat in the Europen region even more complicated, supporting Orlistat's price tendency in Germany. With this, the prices of Orlistat were assessed at USD 385450/MT CFR Hamburg.
For the Quarter Ending June 2022
North America
The North American region showcased a increasing price trend of Orlistat API in the market during the second Quarter of 2022. The resurgence of the covid-19 pandemic in China resulted in a temporary lockdown, causing the shutdown of Industries and positively affecting the prices of Orlistat in the market. Furthermore, the increased downstream demand from Various Pharma and biopharmaceutical industries resulted in upsurged Orlistat prices in the market. Moreover, the increased upstream derivative Lipstatin prices resulted in the price increament downstream Orlistat. Since the lockdown imposed in China, trading activities were hampered, causing freight charges to rise, increasing the prices of Orlistat. In addition, the prices surged at the end of the second quarter i.e., in June with the settlement of USD 386500/MT CFR Los Angeles in Untied States.
Asia Pacific
The Orlistat market showcased a escalated sentiment in its prices during the second Quarter of 2022 in the Asia Pacific region, backed by increased downstream demand observed amid the resurgence of the Covid-19 pandemic in China. Furthermore, the increased trading activities observed from China to other regions affected the market positively in Orlistat prices. Increased demand resulted in shortage of inventories with the suppliers in the domestic market, primarily affecting orlistat prices. Towards the termination of the second Quarter in June, the price surged as the demand increased, leading to a shortage of Inventories. Hence, the China Market settled at USD 370000/MT FOB Shanghai in June.
Europe
In the Second Quarter of 2022, the Europe Orlistat API market showcased mixed sentiments. The increased downstream demand from various pharmaceutical and Biopharmaceutical industries resulted in the price increase of Orlistat. The strong buying activities observed in the domestic market resulted in Orlistat API's price increment. Additionally, prices for Upstream derivative lipstatin added another factor that results in orlistat price increase in the market. Furthermore, with the termination of Q2 the prices recorded for Orlistat in Germany with declining tendency was settled at USD 425130/MT CFR Hamburg.
